| NK-1抑制剂预防头颈部恶性肿瘤PF方案化疗相关恶心、呕吐的疗效观察 |
| 投稿时间：2016-04-14 修订日期：2016-04-14 点此下载全文 |
| 引用本文：田欣,宣莹,胡天玉,曾越灿,吴荣,张振勇.NK-1抑制剂预防头颈部恶性肿瘤PF方案化疗相关恶心、呕吐的疗效观察[J].医学研究杂志,2016,45(11):49-53 |
| DOI：
10.11969/j.issn.1673-548X.2016.11.013 |
| 摘要点击次数: 1040 |
| 全文下载次数: 895 |
|
| 基金项目:国家自然科学基金资助项目（81201803） |
|
| 中文摘要:目的 观察在头颈部恶性肿瘤PF方案（顺铂+5-氟尿嘧啶）化疗过程中应用NK-1抑制剂阿瑞匹坦（aprepitant）的止吐疗效及不良反应。方法 56例需行PF方案静脉化疗的头颈部恶性肿瘤患者，随机分为实验组及对照组，各28例。实验组患者接受NK-1抑制剂阿瑞匹坦+5-HT3受体拮抗剂格拉司琼+地塞米松的三药联合方案预防止吐，对照组接受5-HT3受体拮抗剂格拉司琼+地塞米松的两药联合方案预防止吐。1个化疗周期结束后评估两组患者的恶心、呕吐缓解情况及相关不良反应。结果 56例患者均按期完成化疗，在急性恶心、呕吐控制情况上，实验组均高于对照组，完全缓解率（CR）分别为57.1% vs 50.0%、50.0% vs 42.9%，有效率（RR）分别为82.1% vs 71.4%和78.6% vs 67.9%，差异无统计学意义（P>0.05）。在延迟性恶心、呕吐控制情况上，实验组与对照组完全缓解率CR分别为50.0% vs 21.4%、53.6% vs 25.0%，有效率（RR）分别为78.6% vs 46.4%、82.1% vs 53.6%，实验组明显高于对照组，差异有统计学意义（P<0.05）。两组患者主要不良反应均为轻度，差异无统计学意义（P>0.05）。结论 本研究表明含NK-1抑制剂阿瑞匹坦的三药联合方案预防头颈部恶性肿瘤PF方案化疗引起的急性期及延迟期恶心、呕吐安全有效，可在临床进一步研究推广。 |
| 中文关键词:NK-1抑制剂阿瑞匹坦 头颈部恶性肿瘤 PF方案化疗 恶心、呕吐 |
| |
| Clinical Observation of NK1 Receptor Antagonist Aprepitant for the Prevention of Nausea and Vomiting Induced by PF Chemotherapy Regimen with Head and Neck Cancer |
|
|
| Abstract:Objective To observe the antiemetic effects and adverse effects of NK1 Receptor Antagonist aprepitant for the prevention of nausea and vomiting induced by PF chemotherapy regimen with head and neck cancer. Methods Totally 56 patients with head and neck cancer were randomly divided into the experimental group and the control group,with 28 cases in each group.All the patients in the two groups received PF regimen chemotherapy(cisplatin and 5-FU).The antiemetic regimen for experimental group consisted of aprepitant, 5-HT3 receptor antagonist granisetron and dexamethasone.Control group was 5-HT3 receptor antagonist granisetron and dexamethasone; The antiemetic effects and adverse effects were evaluated after 1 cycle chemotherapy. Results All 56 patients completed chemotherapy. The CR and RR rates of acute nausea and vomiting in the experimental group and the control group were 57.1% vs 50.0%,50.0% vs 42.9%,82.1% vs 71.4%,78.6% vs 67.9%.There was no difference between them. The CR and RR rates of delayed nausea and vomiting in the experimental group and the control group were 50.0% vs 21.4%, 53.6% vs 25.0%,78.6% vs 46.4%,82.1% vs 53.6%,there were statistical difference between them.There was not significant difference between two groups in respect of adverse reactions. Conclusion NK1 receptor antagonist aprepitant combined with5-HT3 receptor antagonist and dexamethasone has a better antiemetic effects for the prevention of nausea and vomiting induced by PF chemotherapy regimen with head and neck cancer, so it is worth to be popularized in clinical research. |
| keywords:NK1 receptor antagonist aprepitant Head and neck cancer PF chemotherapy regimen Nausea and vomiting |
| 查看全文 查看/发表评论 下载PDF阅读器 |
